{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:37:03Z","timestamp":1795027023477,"version":"4.10.2"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22JC1410402"],"award-info":[{"award-number":["22JC1410402"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171421"],"award-info":[{"award-number":["82171421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371432,92249302"],"award-info":[{"award-number":["82371432,92249302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.neuropharm.2025.110659","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:28:23Z","timestamp":1756308503000},"page":"110659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model"],"prefix":"10.1016","volume":"280","author":[{"given":"Meng-Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Heng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Mei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Tao","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9483-3027","authenticated-orcid":false,"given":"Wen-Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.neuropharm.2025.110659_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer's disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110659_bib2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s13311-021-01018-5","article-title":"Neuroprotection of Exendin-4 by enhanced autophagy in a parkinsonian rat model of \u03b1-Synucleinopathy","volume":"18","author":"Bu","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110659_bib3","first-page":"4030","article-title":"Brain GLP-1\/IGF-1 signaling and autophagy mediate Exendin-4 protection against apoptosis in type 2 diabetic rats","volume":"55","author":"Candeias","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110659_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3233\/JAD-180721","article-title":"Tau biology, tauopathy, traumatic brain injury, and diagnostic challenges","volume":"67","author":"Castellani","year":"2019","journal-title":"J. Alzheim. Dis. : JAD"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110659_bib5","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","article-title":"Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP\/PS1\/Tau triple transgenic mice","volume":"42","author":"Chen","year":"2017","journal-title":"Neurochem. Res."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110659_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110659_bib7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.neurobiolaging.2013.12.023","article-title":"Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia","volume":"35","author":"Cook","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110659_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuropharm.2025.110659_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neuro.2016.06.001","article-title":"Developmental exposure to lead (pb) alters the expression of the human tau gene and its products in a transgenic animal model","volume":"55","author":"Dash","year":"2016","journal-title":"Neurotoxicology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110659_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00429-020-02189-1","article-title":"Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain","volume":"226","author":"Farkas","year":"2021","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2025.110659_bib11","series-title":"Wegovy\u00ae (Semaglutide) Prescribing Information","year":"2023"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110659_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110659_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-4-13","article-title":"The role of tau in neurodegeneration","volume":"4","author":"Gendron","year":"2009","journal-title":"Mol. Neurodegener."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110659_bib14","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/cne.23282","article-title":"Glucagon\u2010like peptide\u20101 in the rat brain: distribution of expression and functional implication","volume":"521","author":"Gu","year":"2013","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110659_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainres.2015.12.052","article-title":"The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy","volume":"1634","author":"Hansen","year":"2016","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110659_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110659_bib17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/brain\/aws013","article-title":"Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies","volume":"135","author":"Irwin","year":"2012","journal-title":"Brain : J. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110659_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but May be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.neuropharm.2025.110659_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fncel.2014.00022","article-title":"Insulin dysfunction and tau pathology","volume":"8","author":"Khoury","year":"2014","journal-title":"Front. Cell. Neurosci."},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110659_bib20","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1007\/s00259-022-05898-3","article-title":"A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model","volume":"49","author":"Kimura","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110659_bib21","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cne.23234","article-title":"Synaptic alterations in the rTg4510 mouse model of tauopathy","volume":"521","author":"Kopeikina","year":"2013","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110659_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2025.110659_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123688","article-title":"Novel LC-MS\/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats","volume":"1221","author":"Lee","year":"2023","journal-title":"J. Chromatogr. B"},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2025.110659_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejphar.2011.11.005","article-title":"(Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains","volume":"674","author":"Li","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110659_bib25","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces Amyloid-\u03b2 peptide accumulation and cytotoxicity in cellular and animal models of alzheimer's disease","volume":"19","author":"Li","year":"2010","journal-title":"J. Alzheim. Dis."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110659_bib26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11596-020-2284-z","article-title":"Cornel iridoid glycoside suppresses hyperactivity phenotype in rTg4510 mice through reducing tau pathology and improving synaptic dysfunction","volume":"40","author":"Ma","year":"2020","journal-title":"Current Med. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110659_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2025.110659_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejphar.2012.12.012","article-title":"The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain","volume":"700","author":"Parthsarathy","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"46","key":"10.1016\/j.neuropharm.2025.110659_bib30","doi-asserted-by":"crossref","first-page":"10637","DOI":"10.1523\/JNEUROSCI.3279-05.2005","article-title":"Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L)","volume":"25","author":"Ramsden","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110659_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911527","article-title":"Towards a mechanistic model of tau-mediated pathology in tauopathies: what can we learn from cell-based in vitro assays?","volume":"23","author":"Sala-Jarque","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110659_bib32","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon\u2010like peptide\u20101: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"5733","key":"10.1016\/j.neuropharm.2025.110659_bib33","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","article-title":"Tau suppression in a neurodegenerative mouse model improves memory function","volume":"309","author":"SantaCruz","year":"2005","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110659_bib34","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2353\/ajpath.2006.050840","article-title":"Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy","volume":"168","author":"Spires","year":"2006","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110659_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","article-title":"High-contrast in vivo imaging of tau pathologies in alzheimer's and non-alzheimer\u2019s disease tauopathies","volume":"109","author":"Tagai","year":"2021","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110659_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces \u03b1-Synuclein levels in the chronic MPTP mouse model of parkinson's disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110659_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2019.01.103","article-title":"Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3\u03b2","volume":"511","author":"Zhou","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:21:30Z","timestamp":1768512090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"alternative-id":["S0028390825003673"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110659","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110659"}}